Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2009
Date:8/12/2009

AMSTERDAM, August 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2009.

    Highlights

    - Start of the preregistration clinical trial with Glybera(R)
      in Canada following two previous clinical trials
    - Presentation of additional data indicating that Glybera(R) offers
      a clinically important health benefit, accomplished by a significant
      and clinically important reduction in the incidence of acute
      pancreatitis in patients
    - Significant progress in research and development for other
      pipeline projects including hemophilia B, Duchenne muscular dystrophy
      and Parkinson's disease
    - Key financial figures in line with guidance
    - Cash & cash equivalents of EUR 25 million at June 30, 2009

Results comparison

AMT's key financial figures are well within the budgets for the first semester and therefore remain in line with the guidance that the company has given for 2009. The operating loss increased to EUR 9.9 million for the six months ended June 30, 2009, from EUR 9.1 million for the same period in 2008. This difference is primarily due to the increase of research & development costs to EUR 7.1 million from EUR 5.8 million in the same period of 2008. This increase is particularly related to the clinical development and regulatory work on the company's lead product, Glybera(R), as well as increased staffing for this and other programs. General and administrative costs decreased to EUR 2.9 million, from EUR 3.3 million in the first half of 2008, primarily as a result of decreased advisor's fees.

The net loss for the half of 2009 was EUR 9.4 million, as compared to a net loss of EUR 8.1 million for the first half of 2008.

At June 30, 2009, AMT's cash and cash equivalents amounted to EUR 25 million, compared to EUR 34 million at December 31, 2008.

"AMT showed important results in the first half of 2009. We presented additional data showing the clinically important health benefit of our lead product, Glybera(R), while good progress was made in the further development of our pipeline-products and the strengthening of the company. The search process for a new permanent CEO is progressing expeditiously but carefully to ensure the engagement of a capable new CEO. All of this reinforces our position as a leader in gene therapy and gives us a strong foundation for further growth," said Sander van Deventer, CEO of AMT.

Conference call and webcast presentation

AMT will conduct a conference call open to the public today at 2.00 p.m. CET, which will also be webcast. Netherlands dial in: +31 800 949 4517 (toll free); US dial in: +1 866 291 4166 (toll free); UK dial in: +44 800 279 3 39 56 (toll free). To listen to the conference call live via the internet, visit the investor relations portion of the AMT website at http://www.amtbiopharma.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software. Playback of the call will be availably for 24 hours after the call. Dial In: +41 91 612 4330; +44 20 7108 6233; or +1 866 416 2558. The archived webcast also will be available for replay shortly after the close of the call.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise, especially for thousands of rare (orphan) diseases that are caused by one faulty gene. Currently, AMT has a product pipeline with nine products at different stages of development.

Accounting policies

Basis of accounting

The condensed interim financial statement for the period ended June 30, 2009 has been prepared in accordance with IAS 34, 'interim financial reporting'. The accounting policies are consistent with those of the annual financial statements for the year ended December 31, 2008, as described in the annual financial statements for the year ended December 31, 2008.

Please refer to our website http://www.amtbiopharma.com for the condensed interim financial report June 30, 2009.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
3. Amsterdam Molecular Therapeutics Part of Next Biotech Index
4. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
5. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
7. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. SAFC Supply Solutions(R) Announces Raw Materials Line Developed Specifically to Meet Molecular Diagnostics Manufacturing Requirements
11. Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatricas Room Temperature Storage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, Abby Mitchell, ... Excellence in Education Sponsors Teacher Training Program , Bite of Science Dinner Event ... Center for Excellence in Education (CEE) will sponsor a Bite of Science professional ...
(Date:2/5/2016)... DIEGO , Feb. 5, 2016 On ... region,s trusted information source for community, health and disaster ... Diego) will integrate to enhance care coordination and ... to the services they need and to better connect ... improve care.   San Diego ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... and compliance training, today announced an interactive FDA compliance training course, ... RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now conveniently available ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... and triple quad LC-MS, host live demos and poster sessions, and present on ... exhibition. The conference takes place March 6 to 10 at the Georgia World ...
Breaking Biology Technology:
(Date:2/3/2016)... 3, 2016 --> ... report "Automated Fingerprint Identification System Market by Component (Hardware ... (Banking & Finance, Government, Healthcare, and Transportation) and Geography ... market is expected to be worth USD 8.49 Billion ... 2015 and 2020. The transformation and technology evolution from ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/1/2016)... 1, 2016  Today, the first day of American ... to develop a first of its kind workplace health ... Watson. In the first application of Watson ... IBM ), and Welltok will create a new offering ... cognitive analytics, delivered on Welltok,s health optimization platform. The ...
Breaking Biology News(10 mins):